Japan and China Biopharma: AI Accelerates Drug Development and Lowers Costs, Offering Large Pharma >10% Earnings Upside
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Artificial intelligence is rapidly transforming clinical drug development, with 30% of pharmaceutical companies having already implemented AI tools in 2025. The FDA is actively integrating AI into its regulatory processes, including deploying agentic AI by early 2026. According to Bernstein, AI can optimize trial protocols, accelerate patient recruitment, reduce dropout rates, and expedite regulatory filings. These efficiencies are expected to shorten drug development timelines by approximately 18 months and reduce R&D costs by around 5%. For Japanese biopharma companies, this translates to an operating profit upside of over 10%, while asset-level NPVs could rise by more than 15%. Major beneficiaries among Japanese large-cap pharma include Chugai, Daiichi Sankyo, Eisai, Astellas, Shionogi, and Takeda.
In China, the combination of AI, supportive policies, and infrastructure is further accelerating R&D efficiency. The timeline from preclinical stages to Phase I completion in China typically takes 3–4 years, roughly twice as fast as in the US. Bernstein estimates that for leading Chinese firms like BeiGene and Hengrui Medicine, AI could drive 20–30% in R&D savings, 10–15% revenue improvements, and approximately 10–20% earnings growth, driven by 1–2 years faster time-to-market.
Bernstein notes that AI enhances, rather than disrupts, pharma moats. Key ratings include Chugai (Outperform, JPY 9,900), BeiGene (Outperform, USD 412), and Hengrui (Outperform, CNY 74).